|
1
|
Elinav E, Nowarski R, Thaiss CA, et al:
Inflammation-induced cancer: crosstalk between tumours, immune
cells and microorganisms. Nat Rev Cancer. 13:759–771. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ridnour LA, Cheng RY, Switzer CH, et al:
Molecular pathways: toll-like receptors in the tumor
microenvironment - poor prognosis or new therapeutic opportunity.
Clin Cancer Res. 19:1340–1346. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Akira S and Takeda K: Toll-like receptor
signalling. Nat Rev Immunol. 4:499–511. 2004. View Article : Google Scholar
|
|
4
|
Karin M, Lawrence T and Nizet V: Innate
immunity gone awry: linking microbial infections to chronic
inflammation and cancer. Cell. 124:823–835. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Belmont L, Rabbe N, Antoine M, et al:
Expression of TLR9 in tumor-infiltrating mononuclear cells enhances
angiogenesis and is associated with a worse survival in lung
cancer. Int J Cancer. 765–777. 2013.PubMed/NCBI
|
|
6
|
Vacchelli E, Eggermont A, Sautes-Fridman
C, et al: Trial Watch: Toll-like receptor agonists for cancer
therapy. Oncoimmunology. 2:e252382013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rothenberg SM and Ellisen LW: The
molecular pathogenesis of head and neck squamous cell carcinoma. J
Clin Invest. 122:1951–1957. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bonner JA, Harari PM, Giralt J, et al:
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head
and neck. N Engl J Med. 354:567–578. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Posner MR, Hershock DM, Blajman CR, et al:
Cisplatin and fluorouracil alone or with docetaxel in head and neck
cancer. N Engl J Med. 357:1705–1715. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Amornphimoltham P, Patel V,
Leelahavanichkul K, et al: A retroinhibition approach reveals a
tumor cell-autonomous response to rapamycin in head and neck
cancer. Cancer Res. 68:1144–1153. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Szczepanski MJ, Czystowska M, Szajnik M,
et al: Triggering of Toll-like receptor 4 expressed on human head
and neck squamous cell carcinoma promotes tumor development and
protects the tumor from immune attack. Cancer Res. 69:3105–3113.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mao L, Hong WK and Papadimitrakopoulou VA:
Focus on head and neck cancer. Cancer Cell. 5:311–316. 2004.
View Article : Google Scholar
|
|
13
|
Easton JB and Houghton PJ: mTOR and cancer
therapy. Oncogene. 25:6436–6446. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Faivre S, Kroemer G and Raymond E: Current
development of mTOR inhibitors as anticancer agents. Nat Rev Drug
Discov. 5:671–688. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jimeno A, Rudek MA, Kulesza P, et al:
Pharmacodynamic-guided modified continuous reassessment
method-based, dose-finding study of rapamycin in adult patients
with solid tumors. J Clin Oncol. 26:4172–4179. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Decaens T, Luciani A, Itti E, et al: Phase
II study of sirolimus in treatment-naive patients with advanced
hepatocellular carcinoma. Dig Liver Dis. 44:610–616. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Huang S, Bjornsti MA and Houghton PJ:
Rapamycins: mechanism of action and cellular resistance. Cancer
Biol Ther. 2:222–232. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Molinolo AA, Hewitt SM, Amornphimoltham P,
et al: Dissecting the Akt/mammalian target of rapamycin signaling
network: emerging results from the head and neck cancer tissue
array initiative. Clin Cancer Res. 13:4964–4973. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Le Tourneau C, Faivre S and Siu LL:
Molecular targeted therapy of head and neck cancer: review and
clinical development challenges. Eur J Cancer. 43:2457–2466.
2007.PubMed/NCBI
|
|
20
|
Dobashi Y, Suzuki S, Matsubara H, et al:
Critical and diverse involvement of Akt/mammalian target of
rapamycin signaling in human lung carcinomas. Cancer. 115:107–118.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sun Q, Liu Q, Zheng Y, et al: Rapamycin
suppresses TLR4-triggered IL-6 and PGE(2) production of colon
cancer cells by inhibiting TLR4 expression and NF-kappaB
activation. Mol Immunol. 45:2929–2936. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Maukonen J, Mätto J, Suihko ML, et al:
Intra-individual diversity and similarity of salivary and faecal
microbiota. J Med Microbiol. 57:1560–1568. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wong TS, Liu XB, Wong BY, et al: Mature
miR-184 as potential oncogenic microRNA of squamous cell carcinoma
of tongue. Clin Cancer Res. 14:2588–2592. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sun Z, Luo Q, Ye D, et al: Role of
toll-like receptor 4 on the immune escape of human oral squamous
cell carcinoma and resistance of cisplatin-induced apoptosis. Mol
Cancer. 11:332012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhong LP, Yang X, Zhang L, et al:
Overexpression of insulin-like growth factor binding protein 3 in
oral squamous cell carcinoma. Oncol Rep. 20:1441–1447.
2008.PubMed/NCBI
|
|
26
|
He W, Liu Q, Wang L, et al: TLR4 signaling
promotes immune escape of human lung cancer cells by inducing
immunosuppressive cytokines and apoptosis resistance. Mol Immunol.
44:2850–2859. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li X, Jiang S and Tapping RI: Toll-like
receptor signaling in cell proliferation and survival. Cytokine.
49:1–9. 2009. View Article : Google Scholar
|
|
28
|
Yu L and Chen S: Toll-like receptors
expressed in tumor cells: targets for therapy. Cancer Immunol
Immunother. 57:1271–1278. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chen R, Alvero AB, Silasi DA and Mor G:
Inflammation, cancer and chemoresistance: taking advantage of the
toll-like receptor signaling pathway. Am J Reprod Immunol.
57:93–107. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Erridge C: Endogenous ligands of TLR2 and
TLR4: agonists or assistants? J Leukoc Biol. 87:989–999. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sun Q, Zheng Y, Liu Q and Kao X: Rapamycin
reverses TLR4 signaling-triggered tumor apoptosis resistance by
disrupting Akt-mediated Bcl-xL upregulation. Int Immunopharmacol.
8:1854–1858. 2008. View Article : Google Scholar : PubMed/NCBI
|
